Clinical trial
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal…
NCT00010270 · University Hospital Freiburg, Other · Unknown status
Key facts
| NCT number | NCT00010270 |
|---|---|
| Title | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer |
| Official title | A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma |
| Lead sponsor | University Hospital Freiburg, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | LMB-9 immunotoxin |
| Enrollment | 50 |
| Start date | Apr 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: